Categories: News

Tarus Therapeutics Receives Clearance From the FDA To Initiate Clinical Trial of TT-10 (A2AR Antagonist) in Cancer Patients

NEW YORK, NY / ACCESSWIRE / April 6, 2021 / Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy, today announced that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to proceed with a clinical study of TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR).

Tarus plans to initiate a Phase 1a/1b study in the third quarter of 2021 to evaluate TT-10 in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.

“This IND clearance is a key milestone for Tarus as we continue to advance our portfolio of adenosine receptor antagonists for cancer immunotherapy. We are pleased to be entering the clinic with our potentially best-in-class A2AR antagonist,” said Sushant Kumar, Ph.D., Chief Executive Officer, Tarus Therapeutics. “This is a very exciting moment for the Tarus team, and we look forward to sharing further updates on the clinical development of TT-10.”

About Tarus Therapeutics Inc.

Tarus is developing small molecule inhibitors of A2AR, A2BR, and Dual A2AR/A2BR inhibitors for cancer immunotherapy and select non-oncology indications. The Company has the most comprehensive portfolio of adenosine receptor antagonists in development, with both first-in-class and best-in-class programs. More information can be found at www.tarustx.com.

CONTACT:
Tarus Therapeutics, Inc.
Sushant Kumar, PhD
President & CEO
info@tarustx.com

SOURCE: Tarus Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/639061/Tarus-Therapeutics-Receives-Clearance-From-the-FDA-To-Initiate-Clinical-Trial-of-TT-10-A2AR-Antagonist-in-Cancer-Patients

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

11 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

12 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

15 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

15 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

15 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

15 minutes ago